دورية أكاديمية
NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients
| العنوان: | NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients |
|---|---|
| المؤلفون: | Pallarès, Victor, Hoyos, Montserrat, Chillón, M. del Carmen, Barragán, Eva, Prieto-Conde, Isabel, Llop, Marta, Céspedes, María Virtudes, Nomdedéu, Josep F., Brunet, Salut, Sanz, Miguel Ángel, González, Marcos, Sierra, Jorge, Casanova, Isolda, Mangues, Ramon |
| المساهمون: | Josep Carreras Leukemia Foundation, Generalitat de Catalunya, Fundació La Marató de TV3, Fundació Privada Cellex, Instituto de Salud Carlos III, European Commission, Asociación Española Contra el Cáncer |
| بيانات النشر: | Impact Journals |
| سنة النشر: | 2017 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Acute myeloid leukemia, Nedd9, Intermediate-risk, Bcar1, Prognostic factor |
| الوصف: | Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients. ; This work was supported by Instituto de Salud Carlos III (Co-funding from FEDER) [CD13/00074 to V.P., PI15/00378 to R.M., FIS PI11/00872, RD12/0036/0071 and FIS PI14/00450 to J.S., PIE15/00028 to R.M. and J.S., RD12/0036/0069 to M.G.D., ISCIII-PS13/1640 and RD12/0036/0014 to M.A.S.]; CIBER-BBN [CBV6/01/1031 and Nanomets3 to R.M.]; Generalitat de Catalunya [PERIS SLT002/16/00433 to J.S.]; AGAUR [2014-SGR-1041, 2014PROD0005 to R.M. and 2014-SGR-1281 to J.S.]; Fundació La Marató TV3 [416/C/2013-2030 to R.M., 100830/31/32 to J.S., M.G.D. and M.A.S.]; Josep Carreras Leukemia Research Institute [P/AG 2014 to R.M.]; Spanish Health Research Program ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | Publisher's version; https://doi.org/10.18632/oncotarget.18537Test; Sí; e-issn: 1949-2553; Oncotarget 8(44): 76003-76014 (2017); http://hdl.handle.net/10261/169144Test; http://dx.doi.org/10.13039/501100000780Test; http://dx.doi.org/10.13039/501100005677Test; http://dx.doi.org/10.13039/501100002809Test; http://dx.doi.org/10.13039/100008666Test; http://dx.doi.org/10.13039/501100004587Test |
| DOI: | 10.18632/oncotarget.18537 |
| DOI: | 10.13039/501100000780 |
| DOI: | 10.13039/501100005677 |
| DOI: | 10.13039/501100002809 |
| DOI: | 10.13039/100008666 |
| DOI: | 10.13039/501100004587 |
| الإتاحة: | https://doi.org/10.18632/oncotarget.18537Test https://doi.org/10.13039/501100000780Test https://doi.org/10.13039/501100005677Test https://doi.org/10.13039/501100002809Test https://doi.org/10.13039/100008666Test https://doi.org/10.13039/501100004587Test http://hdl.handle.net/10261/169144Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.88AFBE7B |
| قاعدة البيانات: | BASE |
| DOI: | 10.18632/oncotarget.18537 |
|---|